Compare HIW & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIW | OCUL |
|---|---|---|
| Founded | 1978 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.4B |
| IPO Year | 1994 | 2014 |
| Metric | HIW | OCUL |
|---|---|---|
| Price | $27.56 | $11.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $31.00 | $22.56 |
| AVG Volume (30 Days) | 1.4M | ★ 3.1M |
| Earning Date | 02-10-2026 | 11-04-2025 |
| Dividend Yield | ★ 7.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $811,773,000.00 | $55,783,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.57 | $11.96 |
| P/E Ratio | $22.79 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.19 | $5.79 |
| 52 Week High | $32.76 | $16.44 |
| Indicator | HIW | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 63.94 | 38.41 |
| Support Level | $25.50 | $10.92 |
| Resistance Level | $26.14 | $13.06 |
| Average True Range (ATR) | 0.48 | 0.51 |
| MACD | 0.27 | -0.24 |
| Stochastic Oscillator | 100.00 | 17.47 |
Highwoods Properties Inc is a real estate investment trust engaged in the acquisition, ownership, management, and leasing of properties in urban areas throughout the Southern United States. In terms of total square footage, the vast majority of the company's real estate portfolio comprises office buildings in terms. Highwoods Properties derives nearly all of its income in the form of rental revenue from the tenants of its buildings. The majority of this revenue comes from its holdings in the urban markets of Atlanta, Raleigh, Nashville, and Tampa. These cities also account for the majority of the square footage under the company's ownership. Highwoods Properties customers include the U.S. Government, financial services firms, industrial supply retailers, and healthcare companies.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.